Interest of β-blockers in patients with right ventricular systemic dysfunction

Bouallal, Rachid; Godart, François; Francart, Charles; Richard, A.; Foucher-Hossein, Claude; Lions, Christophe

doi:10.1017/s1047951110000764

Cited by 41 publications

(27 citation statements)

References 20 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Positive RV remodeling 47 vs neutral or possible worsening function, 48 improved exercise duration, 47 improved NYHA functional class 49, 50 and QOL, 50 protective against appropriate shocks 41 …”

Section: Figmentioning

confidence: 99%

Management of Heart Failure in Adult Congenital Heart Disease

Sabanayagam

Cavus

Williams

et al. 2018

Heart Failure Clinics

View full text Add to dashboard Cite

Section: Figmentioning

confidence: 99%

Management of Heart Failure in Adult Congenital Heart Disease

Sabanayagam

Cavus

Williams

et al. 2018

Heart Failure Clinics

View full text Add to dashboard Cite

“…BOUALLAL et al [22] demonstrated the beneficial effects of β-blockers in RV dysfunction, with improvement of RV ejection fraction and NYHA class. However, the patients in that study had RV dysfunction secondary to congenital heart diseases.…”

Section: Figurementioning

confidence: 99%

Outcomes of β-blocker use in pulmonary arterial hypertension: a propensity-matched analysis

et al. 2015

View full text Add to dashboard Cite

The utility and safety of β-blockers in pulmonary hypertension is controversial. Anecdotal reports suggest that β-blockers may be harmful in these patients. The aim of our study was to evaluate outcomes of β-blocker use in pulmonary hypertension.We reviewed patients from our pulmonary hypertension registry between 2000 and 2011. Patients who continued to use β-blockers were compared to those who never used β-blockers for all-cause mortality, time to clinical worsening events, defined as death, lung transplantation and hospitalisation due to pulmonary hypertension. We also evaluated the effect of β-blockers on 6-min walking distance and New York Heart Association (NYHA) functional class.133 patients used β-blockers and 375 patients never used β-blockers. Mean±SD age was 57±16 years and the median follow-up period was 78 months. Propensity-matched analysis showed that the adjusted odds ratio (95% CI) for mortality with β-blocker use was 1.13 (0.69-1.82) and for clinical worsening events was 0.96 (0.55-1.68). No significant difference was noted in probability of survival and time to clinical worsening events. Patients on β-blockers walked a shorter distance on follow-up 6 min walk test; follow-up NYHA class was similar between groups.Pulmonary hypertension patients receiving β-blockers had a similar survival and time to clinical worsening events compared to patients not receiving them. Functional outcomes were similar, although β-blocker use was associated with a tendency towards shorter walking distance. @ERSpublications β-blocker use does not affect survival, symptom worsening or functional capacity in pulmonary hypertension

show abstract

“…Although there are no randomized control trials in this patient population, evidence based therapies in heart failure with reduced ejection fraction have been applied, which include angiotensin converting enzyme inhibitor or angiotensin II receptor blocker and beta-blocker therapies [14][15][16][17][18][19]. There is no evidence for digoxin; however, it can be used.…”

Section: Medical and Device Therapymentioning

confidence: 99%

Ventricular Assist Devices in Patients with Systemic Right Ventricular Failure due to Congenitally Corrected Transposition of the Great Arteries

Sehgal¹,

Ahluwalia²

2017

J Clin Exp Cardiolog

View full text Add to dashboard Cite

Congenitally corrected transposition of the great arteries is increasingly recognized as an adult congenital heart problem. Although early atrial switch surgical repairs resulted in improved overall survival, these patients are further predisposed to systemic ventricular failure in their fourth and fifth decades of life. Early diagnosis and management of systemic ventricular dysfunction are often challenging. Ventricular assist devices may become a mainstay endstage treatment option for these patients as a destination therapy or a bridge to heart transplantation.

show abstract

Interest of β-blockers in patients with right ventricular systemic dysfunction

Abstract: In patients with cardiac failure due to systemic right ventricular dysfunction, β-blockers improve New York Heart Association class, quality of life, and systemic right ventricular ejection fraction assessed by radionuclide ventriculography.

Cited by 41 publications

References 20 publications

Management of Heart Failure in Adult Congenital Heart Disease

Management of Heart Failure in Adult Congenital Heart Disease

Outcomes of β-blocker use in pulmonary arterial hypertension: a propensity-matched analysis

Ventricular Assist Devices in Patients with Systemic Right Ventricular Failure due to Congenitally Corrected Transposition of the Great Arteries

Contact Info

Product

Resources

About